MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Beliefs and knowledge on Parkinson’s disease (PD) among people with PD, the public and traditional healers in Western Cape, South Africa

    J. Mokaya, J. Carr (Tygerberg, South Africa)

    Objective: To determine belief systems and knowledge about PD among patients with PD, among the public and among traditional healers. Background: Parkinson's disease (PD) is…
  • 2016 International Congress

    Progressive encephalomyelitis with rigidity and myoclonus (PERM) in an intellectually disabled patient initially misdiagnosed as neuroleptic malignant syndrome (NMS)

    Z. Xu, K. Prasad, T. Yeo (Singapore, Singapore)

    Objective: This is the first reported case of PERM made in a patient with profound mental retardation and we highlight the unusual features of his…
  • 2016 International Congress

    The communicative effectiveness survey-revised (CESR): An objective measure of communicative participation for people with Parkinson’s disease

    N.J. Donovan (Baton Rouge, LA, USA)

    Objective: To study the item-level psychometric properties of the Communicative Effectiveness Survey-Revised (CESR), the first patient reported outcome measure for people with Parkinson's disease (PD)…
  • 2016 International Congress

    The differentiated treatment of Parkinson’s disease in patients with concomitant diabetes mellitus(DM) type 2

    F.S. Akhmedova, M.K.U. Tukhtamishev (Tashkent, Uzbekistan)

    Objective: To study the state of lipid metabolism in PD patients with concomitant type 2 diabetes with different glucose tolerance and the influence of the…
  • 2016 International Congress

    Effect of dopamine and L-3,4 – dihydroxyphenylalanine in treatment of experimental parkinsonism

    M.U. Kulmanova (Tashkent, Uzbekistan)

    Objective: To study effect of dopamine and L-3,4 - dihydroxyphenylalanine in treatment of experimental parkinsonism. Background: Prospects of treatment of Parkinson's disease are also closely…
  • 2016 International Congress

    Improving the experience of diagnosis in Parkinson’s disease

    C. Carroll, B. Blight, V. Evans, N. Hawkes, J. Davis (Plymouth, United Kingdom)

    Objective: To identify areas in which patient experience of being diagnosed with Parkinson's can be improved. Background: Receiving a Parkinson's diagnosis can leave patients feeling…
  • 2016 International Congress

    Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease

    L. Zhang, M. Wang, J. Zhu, Y. Pan, J. Dong (Nanjing, People's Republic of China)

    Objective: To Evaluate:prepared a MPTP/p induced mouse subacute model of PD, and explore the modulatory effect of H2S on monoamine and amino acid neurotransmitters in…
  • 2016 International Congress

    Inhibition of cathepsin D enhances the autophagy lysosome pathway dysfunction and α-synuclein aggregation in experimental parkinsonism

    L. Li, Y.P. Yang, L. Gao, Y. Song, Z. Liang (Suzhou, People's Republic of China)

    Objective: To explore the mechanism of CTSD inhibition in the dysfunction of autophagy-lysosome pathway and aggregation of α-synuclein in Parkinson's disease. Background: α-synuclein, the main…
  • 2016 International Congress

    Effect of repeated intravenous amantadine infusions in patients with Parkinson’s disease

    A. Khlebtovsky, I. Steiner, R. Djaldetti, T. Treves (Petach Tikva, Israel)

    Objective: To examine the long-term effect of repeated boosts of intravenous amantadine in patients with PD with and without response fluctuations and dyskinesias. Background: Amantadine…
  • 2016 International Congress

    Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease

    C. Mahapatra, R. Manchanda (Mumbai, India)

    Objective: Understanding the drug effects with respect to various ion channels on subthalamic nucleus (STN) cells is the key to safety pharmacology assessment. Here our…
  • « Previous Page
  • 1
  • …
  • 152
  • 153
  • 154
  • 155
  • 156
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley